Pfizer–BioNTech COVID-19 vaccine
mRNA vaccine against COVID-19 from BioNTech in cooperation with Pfizer
Press Enter · cited answer in seconds
0 sources
Pfizer–BioNTech COVID-19 vaccine
Summary
Pfizer–BioNTech COVID-19 vaccine is a funded product[1]. It ranks in the top 9% of funded_product entities by monthly Wikipedia readership (1,745 views/month).[2]
Key Facts
- Pfizer–BioNTech COVID-19 vaccine's instance of is recorded as funded product[3].
- Pfizer–BioNTech COVID-19 vaccine's instance of is recorded as pharmaceutical product[4].
- Pfizer–BioNTech COVID-19 vaccine is owned by Pfizer[5].
- Pfizer–BioNTech COVID-19 vaccine is owned by BioNTech[6].
- Pfizer–BioNTech COVID-19 vaccine's manufacturer is recorded as Pfizer[7].
- Pfizer–BioNTech COVID-19 vaccine's manufacturer is recorded as Rentschler Biopharma SE[8].
- Pfizer–BioNTech COVID-19 vaccine's manufacturer is recorded as Behringwerke[9].
- Pfizer–BioNTech COVID-19 vaccine's manufacturer is recorded as BioNTech[10].
- Pfizer–BioNTech COVID-19 vaccine's manufacturer is recorded as Baxter International[11].
- Pfizer–BioNTech COVID-19 vaccine's developer is recorded as BioNTech[12].
- Pfizer–BioNTech COVID-19 vaccine's developer is recorded as Pfizer[13].
- Pfizer–BioNTech COVID-19 vaccine is a type of COVID-19 vaccine[14].
- Pfizer–BioNTech COVID-19 vaccine is a type of RNA vaccine[15].
- Pfizer–BioNTech COVID-19 vaccine's Commons category is recorded as Tozinameran[16].
- Pfizer–BioNTech COVID-19 vaccine's route of administration is recorded as intramuscular injection[17].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults[18].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report[19].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine[20].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults[21].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults[22].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study[23].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as A Phase I clinical trial of novel coronavirus pneumonia (COVID-19) mRNA Vaccine (BNT162b1) in China[24].
- Pfizer–BioNTech COVID-19 vaccine's described by source is recorded as Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates[25].
- Pfizer–BioNTech COVID-19 vaccine's NCI Thesaurus ID is recorded as C173055[26].
- Pfizer–BioNTech COVID-19 vaccine's side effect is recorded as anaphylaxis[27].
Why It Matters
Pfizer–BioNTech COVID-19 vaccine ranks in the top 9% of funded_product entities by monthly Wikipedia readership (1,745 views/month).[2] It has Wikipedia articles in 28 language editions, a strong signal of global cultural recognition.[28] It is known by 99 alternative names across languages and contexts.[29]